“Business-as-usual” is not a term we use at Akron.
The science behind regenerative medicine is constantly evolving. The key to Akron’s commercial strategy is the ability to respond to a dynamic market, by
1) Mapping the relationship between market and product strategy, and
2) Sustaining a competitive edge by meeting shifting drug regulations and customer demands.
To maintain a leading industry position, Akron is constantly adapting and responding to customers’ changing needs. At Akron Biotech, we are not simply a reagent distributor. We form a relationship, furnishing clients with comprehensive solutions to meet their specific needs. This means we provide regulation-approved raw materials (USP, EP, and JP grades) and biological reagents, from research grade to GMP grade. Furthermore, our products are supported by expert services that ensure regulatory compliance and a shorter time-to-market. Akron differentiates itself on its quality, consistency, and expertise. We’re well placed to grow significantly in a rapidly expanding market.
Akron Biotech was founded in 2006, and is a privately owned company headquartered in South Florida, U.S. Akron has a strategic focus on enabling tools, technologies, and services for the regenerative medicine industry. As a global supplier, Akron manufactures and distributes components and raw materials for cell therapy discovery, development, and commercialization, meeting the industry’s needs worldwide. Our company’s unique business model emphasizes flexibility, quality, and unparalleled service—from research and development through clinical trial, market authorization, and commercial product.
Akron is committed to innovating and delivering the most robust, validated and compliant technologies and solutions to the cell and gene therapy arena.